Skip to Content

Xylem Inc

XYL: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$955.00CgjcqbxQnyjnvmkd

Xylem: Reiterating Narrow Moat Rating and $97 Fair Value Estimate After Evoqua Acquisition

After reviewing our assumptions for Xylem following the completion of its acquisition of Evoqua, we reiterate our narrow moat rating and $97 fair value estimate but downgrade our moat trend rating to stable from positive. We see the name as fairly valued, with the stock currently trading in 3-star territory.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of XYL so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center